CNB and Pharmexil Sign MOU to Boost Legitimate Pharmaceutical Exports and Strengthen Regulatory Cooperation

Singapore’s Central Narcotics Bureau (CNB) and Pharmexil today signed a memorandum of understanding (MOU) to advance legitimate pharmaceutical exports and reinforce regulatory cooperation. The agreement, which aligns the enforcement mission of the CNB with Pharmexil’s commercial operations, seeks to streamline export licensing procedures, improve information sharing, and jointly monitor compliance with international drug control standards. By formalizing a partnership between a government regulator and a private‑sector player, the MOU is intended to reduce the potential for illicit diversion of medicines while encouraging Singapore’s growing pharmaceutical export sector.

Pharmexil, a Singapore‑based manufacturer and distributor of generic and specialty drugs, has been a key contributor to the country’s reputation as a hub for high‑quality pharmaceutical products. The CNB, tasked with preventing the trafficking of controlled substances, has increasingly focused on the export side of the supply chain, where gaps can allow drugs to enter illicit markets. The MOU builds on existing regulatory frameworks such as the Medicines Act and the Singapore Customs